What is hGH Frag 176-191?
hGH Fragment 176-191 is a synthetic peptide, a modified fragment (amino acids 176-191) of the C-terminal part of human growth hormone (hGH). It was created with the aim of isolating the lipolytic (fat-breaking) properties of GH without activating its other physiological effects. In the scientific literature, hGH Frag has been studied as a potential regulator of lipolysis and metabolic balance.
Unlike full-length growth hormone, HGH Frag 176-191 does not show significant activity on IGF-1 levels and does not stimulate tissue growth. Instead, according to scientific studies, the peptide has been associated with stimulation of lipolysis and inhibition of lipogenesis, making it an interesting model for studying metabolic processes related to fat metabolism.
HGH Frag Observations 176-191
In the scientific literature, HGH Frag 176-191 has been studied in relation to:
-
Stimulation of lipolysis - promotes the breakdown of fatty acids in adipocytes
-
Inhibition of lipogenesis - suppresses the accumulation of new fat cells
-
Body weight regulation - being studied as a potential metabolic modulator
-
Maintaining lean muscle mass - without anabolic effects typical of GH
-
Visceral fat reduction - in obesity models
-
Improvement in insulin sensitivity - observed in some preclinical studies
Scientific data
HGH Frag 176-191 has been studied in primarily preclinical models and limited clinical trials. Key scientific observations include:
-
Increased lipolysis in adipocyte cultures and living models
-
Reduction in total and visceral fat without change in IGF-1 levels
-
Lack of effect on glucose homeostasis at low doses
-
No effect on organ and tissue growth
-
Improved lipid metabolism and energy efficiency in some experimental models
Dosage and administration
In the scientific literature, doses quoted range from 250-500 μg daily, administered subcutaneously, often divided into 1-2 applications. The peptide is typically used in short-term research cycles (2-4 weeks) focused on lipolytic mechanisms.
At 5 mg + 3 ml bacteriostatic water:
Concentration = 1.67 mg/ml → 0.06 ml = 100 μg
Example values:
0.06 ml = 100 μg
0.12 ml = 200 μg
0.18 ml = 300 μg
0.24 ml = 400 μg
Application in sports and research settings
HGH Fragment 176-191 is included in the WADA list of controlled substances and is not permitted for use by professional athletes. In a research context, the peptide is used to study lipolytic mechanisms and energy metabolism in various models of metabolic syndrome, obesity, and insulin resistance.
-
Model for studying mechanisms of fat reduction
-
Studies on insulin sensitivity and lipid metabolism
-
Possible synergy with other peptides regulating energy balance
Possible side effects
In research settings, HGH Frag 176-191 is considered well tolerated. The observed reactions are usually mild and transient:
There are no published data on serious side effects at research doses. The effects are dose-dependent and temporary.
The information is based on scientific publications and is for educational purposes only. It is not intended to diagnose, treat or prevent disease.